CR20200375A - Anticuerpos agonistas contra pd-1 y usos de estos - Google Patents

Anticuerpos agonistas contra pd-1 y usos de estos

Info

Publication number
CR20200375A
CR20200375A CR20200375A CR20200375A CR20200375A CR 20200375 A CR20200375 A CR 20200375A CR 20200375 A CR20200375 A CR 20200375A CR 20200375 A CR20200375 A CR 20200375A CR 20200375 A CR20200375 A CR 20200375A
Authority
CR
Costa Rica
Prior art keywords
agonist antibodies
antibodies against
tissues
human
rheumatoid arthritis
Prior art date
Application number
CR20200375A
Other languages
English (en)
Inventor
Pia Pauliina Yachi
Kristin Paige Newburn
Stephanie Marie Truhlar
Qing Chai
Yiqing Feng
Petra Verdino
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CR20200375A publication Critical patent/CR20200375A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

<p>La presente invención se refiere a anticuerpos agonistas anti-PD-1 humana y sus usos para tratar trastornos autoinmunitarios, tales como la artritis reumatoide, o para disminuir el rechazo de células y/o tejidos trasplantados.</p>
CR20200375A 2018-03-02 2019-02-22 Anticuerpos agonistas contra pd-1 y usos de estos CR20200375A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862637643P 2018-03-02 2018-03-02
PCT/US2019/019076 WO2019168745A1 (en) 2018-03-02 2019-02-22 Pd-1 agonist antibodies and uses thereof

Publications (1)

Publication Number Publication Date
CR20200375A true CR20200375A (es) 2020-09-25

Family

ID=65686121

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20200375A CR20200375A (es) 2018-03-02 2019-02-22 Anticuerpos agonistas contra pd-1 y usos de estos

Country Status (26)

Country Link
US (1) US10493148B2 (es)
EP (1) EP3759139A1 (es)
JP (3) JP7071521B2 (es)
KR (2) KR20230079458A (es)
CN (4) CN118846042A (es)
AR (1) AR114127A1 (es)
AU (2) AU2019228474B2 (es)
BR (1) BR112020015983A2 (es)
CA (1) CA3092064C (es)
CL (1) CL2020002180A1 (es)
CO (1) CO2020010188A2 (es)
CR (1) CR20200375A (es)
DO (1) DOP2020000153A (es)
EA (1) EA202091809A1 (es)
EC (1) ECSP20053544A (es)
IL (1) IL276340A (es)
JO (1) JOP20200210A1 (es)
MA (1) MA52414A (es)
MX (1) MX2020009124A (es)
PE (1) PE20210045A1 (es)
PH (1) PH12020551463A1 (es)
SA (1) SA520420082B1 (es)
SG (1) SG11202008437WA (es)
TW (1) TWI708787B (es)
WO (1) WO2019168745A1 (es)
ZA (1) ZA202004601B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017066561A2 (en) * 2015-10-16 2017-04-20 President And Fellows Of Harvard College Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
BR112019018915A2 (pt) 2017-03-15 2020-04-14 Pandion Therapeutics Inc imunotolerância direcionada
AU2018273914A1 (en) 2017-05-24 2019-11-14 Pandion Operations, Inc. Targeted immunotolerance
US10995149B2 (en) 2017-06-05 2021-05-04 Janssen Biotech, Inc. Antibodies that specifically bind PD-1 and methods of use
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
CN112236454B (zh) * 2018-03-20 2022-09-13 上海药明生物技术有限公司 新型抗pd-1抗体
US11162079B2 (en) 2019-05-10 2021-11-02 The Regents Of The University Of California Blood type O Rh-hypo-immunogenic pluripotent cells
US20220213434A1 (en) 2019-05-10 2022-07-07 The Regents Of The University Of California Modified pluripotent cells
AU2020279240A1 (en) 2019-05-20 2021-12-23 Pandion Operations, Inc. MAdCAM targeted immunotolerance
WO2021168192A2 (en) * 2020-02-21 2021-08-26 Pandion Operations, Inc. Tissue targeted immunotolerance with pd-1 agonists or il-2 muteins
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
JP2023522962A (ja) * 2020-04-22 2023-06-01 アイジーエム バイオサイエンシズ インコーポレイテッド Ｐｄ－１アゴニスト多量体結合分子
US20230183347A1 (en) * 2020-05-25 2023-06-15 Foundation For Biomedical Research And Innovation At Kobe PD-1 Agonist-Containing Pharmaceutical Composition for Treating or PReventing TH2-Mediated Disease
CA3181776A1 (en) 2020-05-26 2021-12-02 Boehringer Ingelheim International Gmbh Anti-pd-1 antibodies
KR20240007203A (ko) 2021-05-13 2024-01-16 고에키 자이단 호징 고베 이료 산교 도시 스이신 기코 염증성 질환을 치료 또는 예방하기 위한 항-인간 pd-1 작용제 항체 및 이를 함유하는 의약 조성물
TW202440647A (zh) 2021-11-19 2024-10-16 英商米羅比奧有限公司 經工程改造之pd-1抗體及其用途
WO2023147470A2 (en) * 2022-01-28 2023-08-03 Georgiamune Inc. Antibodies to programmed cell death protein 1 that are pd-1 agonists
AU2023251864A1 (en) * 2022-04-13 2024-10-03 The Regents Of The University Of California Immune cell inhibition by immune checkpoint engagers
WO2024010861A2 (en) * 2022-07-06 2024-01-11 Santa Ana Bio, Inc. Methods and compositions for treating autoimmune, allergic and inflammatory diseases
WO2024040206A2 (en) * 2022-08-19 2024-02-22 Eli Lilly And Company Pd-1 agonist antibodies and methods of treating autoimmune diseases with a pd-1 agonist antibody
EP4580674A2 (en) * 2022-08-30 2025-07-09 Flagship Pioneering Innovations VI, LLC Antigen binding molecules targeting programmed cell death protein 1 (pd-1)
US12030945B2 (en) 2022-10-25 2024-07-09 Seismic Therapeutic, Inc. Variant IgG Fc polypeptides and uses thereof
TW202434625A (zh) * 2022-11-18 2024-09-01 美商美國禮來大藥廠 Lag-3及pd-1/lag-3抗體
CN116284447A (zh) * 2023-02-20 2023-06-23 苏州大学 一种靶向pd1嵌合抗原受体修饰的调节性t细胞及其制备方法与应用
WO2024196694A2 (en) * 2023-03-17 2024-09-26 Eli Lilly And Company Pd-1 agonist antibodies and methods of treating inflammatory or autoimmune skin diseases with a pd-1 agonist antibody
TW202525852A (zh) * 2023-08-18 2025-07-01 美商美國禮來大藥廠 Pd-1促效劑抗體及以pd-1促效劑抗體治療自體免疫疾病之方法
CN119798436A (zh) 2023-10-10 2025-04-11 长春金赛药业有限责任公司 抗pd-1单克隆抗体及其应用
CN120424213A (zh) * 2024-02-02 2025-08-05 英诺湖医药(杭州)有限公司 特异性结合pd-1的单克隆抗体及其医药用途
WO2026008665A1 (en) 2024-07-01 2026-01-08 Vib Vzw Binders of the pd-1•pd-l1 complex and their use

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
US20120269806A1 (en) 2007-08-21 2012-10-25 The General Hospital Corporation Methods of inducing tolerance
AU2009290543B2 (en) * 2008-09-12 2015-09-03 Oxford University Innovation Limited PD-1 specific antibodies and uses thereof
AU2009290544B2 (en) 2008-09-12 2015-07-16 Oxford University Innovation Limited PD-1 specific antibodies and uses thereof
WO2010089411A2 (en) 2009-02-09 2010-08-12 Universite De La Mediterranee Pd-1 antibodies and pd-l1 antibodies and uses thereof
US20130202623A1 (en) 2010-02-16 2013-08-08 Nicolas Chomont Pd-1 modulation and uses thereof for modulating hiv replication
TW201134488A (en) * 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
CN102892786B (zh) 2010-03-11 2016-03-16 Ucb医药有限公司 Pd-1抗体
WO2013022091A1 (ja) * 2011-08-11 2013-02-14 小野薬品工業株式会社 Ｐｄ－１アゴニストからなる自己免疫疾患治療剤
WO2014161509A1 (en) 2013-04-05 2014-10-09 The University Of Hong Kong Novel pd1 isoforms, and uses thereof for potentiating immune responses
PT3177644T (pt) 2014-08-05 2021-01-13 MabQuest SA Reagentes imunológicos que se ligam a pd-1
US9982052B2 (en) 2014-08-05 2018-05-29 MabQuest, SA Immunological reagents
JP6974311B2 (ja) 2015-06-23 2021-12-01 メモリアル スローン ケタリング キャンサー センター 新規ｐｄ−１免疫調節剤
BR112018006237A2 (pt) 2015-09-29 2018-10-09 Celgene Corp proteínas de ligação a pd-1 e métodos de uso das mesmas
PL3368572T5 (pl) 2015-10-02 2026-07-20 Les Laboratoires Servier Przeciwciała anty-PD-1 oraz kompozycje
SI3356404T1 (sl) 2015-10-02 2021-11-30 F. Hoffmann-La Roche Ag Protitelesa proti PD1 in postopki uporabe
CN109152798B (zh) 2015-12-02 2022-10-21 斯特库比股份有限公司 特异于糖基化的pd-1的抗体及其使用方法
US10995149B2 (en) 2017-06-05 2021-05-04 Janssen Biotech, Inc. Antibodies that specifically bind PD-1 and methods of use

Also Published As

Publication number Publication date
SG11202008437WA (en) 2020-09-29
ECSP20053544A (es) 2020-10-30
PH12020551463A1 (en) 2021-09-01
ZA202004601B (en) 2022-03-30
AU2019228474A1 (en) 2020-08-20
JP7071521B2 (ja) 2022-05-19
CA3092064C (en) 2024-01-02
JOP20200210A1 (ar) 2020-08-30
AU2019228474B2 (en) 2023-04-13
JP2023093549A (ja) 2023-07-04
JP7259107B2 (ja) 2023-04-17
SA520420082B1 (ar) 2022-11-11
WO2019168745A1 (en) 2019-09-06
KR20200115614A (ko) 2020-10-07
CN118806891A (zh) 2024-10-22
BR112020015983A2 (pt) 2020-12-15
MX2020009124A (es) 2020-09-28
EA202091809A1 (ru) 2020-11-23
AU2023204569A1 (en) 2023-10-26
PE20210045A1 (es) 2021-01-08
CN111886253B (zh) 2024-08-27
CL2020002180A1 (es) 2021-01-04
TW201942133A (zh) 2019-11-01
CN118903407A (zh) 2024-11-08
IL276340A (en) 2020-09-30
CN118846042A (zh) 2024-10-29
CA3092064A1 (en) 2019-09-06
CO2020010188A2 (es) 2020-08-31
MA52414A (fr) 2021-01-06
JP2022088411A (ja) 2022-06-14
AR114127A1 (es) 2020-07-22
KR102536014B1 (ko) 2023-05-24
TWI708787B (zh) 2020-11-01
CN111886253A (zh) 2020-11-03
JP2021516235A (ja) 2021-07-01
NZ766604A (en) 2024-10-25
EP3759139A1 (en) 2021-01-06
DOP2020000153A (es) 2020-09-15
KR20230079458A (ko) 2023-06-07
US10493148B2 (en) 2019-12-03
US20190270818A1 (en) 2019-09-05

Similar Documents

Publication Publication Date Title
PH12020551463A1 (en) Pd-1 agonist antibodies and uses thereof.
CL2020002613A1 (es) Receptores quiméricos de dll3 y métodos para su uso
MX2024015440A (es) Anticuerpos anti-phf-tau y usos de estos
MX2022004101A (es) Composiciones de oligonucleotidos y metodos de uso de las mismas.
MX395639B (es) Composiciones y métodos para el agotamiento de células cd137+.
MA43603A1 (fr) Récepteurs chimériques et leurs procédés d&#39;utilisation
WO2018234793A3 (en) Antibodies
MY205789A (en) Anti-gdf15 antibodies, compositions and methods of use
UA112417C2 (uk) Мовчазний fc-варіант анти-cd40 антитіла
EA201992610A1 (ru) Экспансия -t-клеток, композиции и способы их применения
EA201391755A1 (ru) Анти-kir антитела для лечения воспалительных заболеваний
MX2020010724A (es) Metodos para preparar composiciones proteicas estables.
EA202092489A1 (ru) СЕЛЕКТИВНЫЙ СТИМУЛЯТОР Treg RUR20kD-IL-2 И РОДСТВЕННЫЕ КОМПОЗИЦИИ
EA201792221A1 (ru) Антитела против сортилина и способы их применения
MX377712B (es) Anticuerpos dirigidos contra il-33 y sus usos.
JOP20210015A1 (ar) تركيبات مضادات fcrn وطرق استخدامها
MX2019008872A (es) Prevencion y tratamiento de da?o o enfermedad osea y cartilago.
CO2022014150A2 (es) Anticuerpos anti-interleucina-33 y usos de estos
MX2021007143A (es) Sintesis de gamma-carbolinas fusionadas con heterociclo sustituido.
ZA202309516B (en) Anti-ccr8 antibodies
MY206121A (en) Dual inhibitors of tim-3 and pd-1 pathways
MX2020010722A (es) Anticuerpos anti-cd40 para uso en la prevencion del rechazo de injertos.
MX2023011725A (es) Anticuerpos anti-cd19 y estructuras car-t.
MX2022015801A (es) Sistemas de expresion de baculovirus.
EA201892005A1 (ru) Композиции и способы для лечения ревматоидного артрита